Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.42 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7808443 | 1.00 | ALDH1A1 (0.48) | ALDH1A1LMNAGAAALOX15TSHR | |
| SCHEMBL3651603 | 0.83 | CA1 (0.47) | ALDH1A1CA1CA2CES2CES1 | |
| SCHEMBL3651604 | 0.83 | CA1 (0.47) | ALDH1A1CA1CA2CES2CES1 | |
| SCHEMBL9575084 | 0.82 | CES1 (0.54) | ALDH1A1TSHRCA1CA2CES2 | |
| SCHEMBL3052475 | 0.82 | CES1 (0.54) | ALDH1A1TSHRCA1CA2CES2 | |
| SCHEMBL3052477 | 0.82 | CES1 (0.54) | ALDH1A1TSHRCA1CA2CES2 | |
| SCHEMBL7807046 | 0.80 | ALOX15 (0.41) | ALDH1A1LMNAGAAALOX15TSHR | |
| SCHEMBL7807050 | 0.80 | ALOX15 (0.41) | ALDH1A1LMNAGAAALOX15TSHR | |
| SCHEMBL27486091 | 0.80 | LMNA (0.43) | ALDH1A1LMNAGAACA1CA2 | |
| SCHEMBL21275410 | 0.77 | CA1 (0.50) | ALDH1A1LMNACA1CA2NR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6306880-B1 | HETEROCYCLIC ALCOHOL DERIVATIVES AS FUNGICIDES | SANKYO COMPANY, LIMITED (JP) | 2001-10-23 | — | — | US | disclosed |
| US-20010031778-A1 | Triazole antifungal agent | SANKYO COMPANY LIMITED (JP) | 2001-10-18 | — | — | US | disclosed |
| US-20010031768-A1 | Triazole antifungal agent | SANKYO COMPANY LIMITED (JP) | 2001-10-18 | — | — | US | disclosed |
| US-6300357-B1 | FOR THERAPY OF MYCOTIC DISEASE OF A HUMAN BEING AND AN ANIMAL | SANKYO COMPANY, LIMITED (JP) | 2001-10-09 | — | — | US | disclosed |
| EP-0841327-B1 | TRIAZOLE ANTIFUNGAL AGENT | SANKYO CO (JP) | 2001-10-04 | — | — | EP | disclosed |
| US-5977152-A | Triazole antifungal agent | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| EP-0841327-A1 | TRIAZOLE ANTIFUNGAL AGENT | SANKYO COMPANY LIMITED (JP) | 1998-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031768-A1 | Triazole antifungal agent | ERG28, RIF1, NAT1 | ALDH1A1 1123/4885LMNA 4508/4885GAA 1679/4885 |
| US-20010031778-A1 | Triazole antifungal agent | ERG28, NAT1, RIF1 | ALDH1A1 893/4885LMNA 4677/4885GAA 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.